Imperagen raises £5M seed round to accelerate AI-driven enzyme engineering

2026-05-21 · Source: Tech.eu - Tech.eu · Field: Technology & Digital — Artificial Intelligence & Machine Learning, Life Sciences & Biology, Robotics & Autonomous Systems · Depth: Intermediate, quick

Summary

Manchester techbio company Imperagen has secured a £5 million seed funding round, led by PXN Ventures with participation from IQ Capital and Northern Gritstone. Established in 2021, Imperagen focuses on accelerating enzyme engineering for diverse markets including pharmaceutical manufacturing, life sciences, and sustainable chemical production. The company's proprietary closed-loop platform integrates quantum physics simulations to predict millions of mutation combinations, problem-specific AI model training, and automated robotics for physical lab testing. This system features a crucial feedback loop where experimental data continuously refines the AI, leading to smarter, more targeted iterations. This approach dramatically improved two enzymes' productivity by 677x and 572x in just five rounds. The new funds will accelerate R&D, scale wet lab operations, expand the AI team, and strengthen go-to-market efforts across its target sectors.

Key takeaway

For Directors of AI/ML evaluating enzyme engineering solutions, Imperagen's £5 million funding validates a powerful closed-loop AI approach. You should consider how integrating quantum simulations with automated wet lab feedback can dramatically accelerate your R&D cycles and de-risk product development. This model demonstrates significant productivity gains, offering a blueprint for rapid, data-driven biocatalysis innovation in your own projects.

Key insights

Imperagen's closed-loop AI platform integrates quantum simulation and automated wet lab feedback to rapidly engineer enzymes, significantly boosting productivity.

Principles

• Enzyme engineering benefits from recursive AI.
• Real-world data refines AI models effectively.
• Closed-loop systems accelerate biotech R&D.

Method

Imperagen's method involves quantum physics simulation for mutation prediction, training problem-specific AI models with these outputs, and automated robotics testing in the lab, with experimental data continuously feeding back to refine the AI.

In practice

• Accelerate pharmaceutical manufacturing.
• Streamline sustainable chemical production.
• Improve personal care product lines.

Topics

• Enzyme Engineering
• AI-driven Biocatalysis
• Quantum Physics Simulation
• Automated Robotics
• Seed Funding
• Industrial Biotechnology
• Pharmaceutical Manufacturing

Best for: Investor, Director of AI/ML, Research Scientist

Related on AIssential

• GPT-5 lowers the cost of cell-free protein synthesis — GPT-5 connected to a robotic lab significantly reduced cell-free protein synthesis costs through autonomous closed-loop optimization.
• Our new initiative to apply quantum science and AI to the life sciences — Google's REPLIQA program funds quantum science and AI research in life sciences to solve complex biological problems.
• AI can design and run thousands of lab experiments without human hands. Humanity isn’t ready for the new risks this brings to biology — AI is rapidly automating biological experimentation, accelerating discovery but also creating significant dual-use biosecurity risks.
• 🔬 Automating Science: World Models, Scientific Taste, Agent Loops — Andrew White — AI agents like Cosmos are automating scientific discovery by integrating literature, data analysis, and experimental feedback loops.
• A geometric foundation model for enzyme retrieval with evolutionary insights — EnzymeCAGE is a geometric foundation model that predicts enzyme function and reaction specificity using structural and evolutionary data.
• “Curing All Disease by next century is too conservative" - Mark Zuckerberg — Integrating frontier AI with frontier biology and open-source tools accelerates disease understanding and personalized therapeutic design.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Tech.eu - Tech.eu.